SERPINH1 and hepatitis C virus infection: BMS-986263 is a lipid nanoparticle delivering small interfering RNA targeting SERPINH1 mRNA, and it has shown promising safety and significant improvement in fibrosis status in a phase II trial for the treatment of advanced fibrosis in hepatitis C patients 54.